Jon Cohen. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Anti-HIV Agents/therapeutic useAntiretroviral Therapy, Highly ActiveCD4-Positive T-Lymphocytes/immunologyCD4-Positive T-Lymphocytes/virologyEnfuvirtideEnzyme Inhibitors/therapeutic useHIV/drug effectsHIV/physiologyHIV Envelope Protein gp41/therapeutic useHIV Infections/drug therapyHIV Infections/immunologyHIV Infections/virologyHistone Deacetylase 1Histone Deacetylase InhibitorsHumansPeptide Fragments/therapeutic useValproic Acid/therapeutic useVirus Latency/drug effects
Substances： See more » Anti-HIV AgentsEnzyme InhibitorsHIV Envelope Protein gp41Histone Deacetylase InhibitorsPeptide FragmentsEnfuvirtideValproic AcidHDAC1 protein, humanHistone Deacetylase 1
Year: 2005 PMID： 16099956 DOI： 10.1126/science.309.5737.999a
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728